|
WO2008119110A1
|
|
Treatment of obesity
|
|
WO2007048186A1
|
|
Leukocyte-binding polypeptides and uses thereof
|
|
WO2007022592A1
|
|
Devices and methods for perfusing an organ
|
|
CN101237879A
|
|
Anticoagulation agent and uses thereof
|
|
EP1906990A1
|
|
Anticoagulation agent
|
|
AU2005242189A1
|
|
Method of modulating gene transcription
|
|
CA2529677A1
|
|
Method of modulating gene transcription
|
|
EP1781179A1
|
|
Treating valvular insufficiency
|
|
WO2005116057A1
|
|
Monoclonal antibody against abca1
|
|
US2006264367A1
|
|
Prevention of fibrosis following cardiac injury
|
|
CA2505569A1
|
|
Attenuation of disorders by aminoglycosides
|
|
AU2005201787A1
|
|
Attenuation of disorders by aminoglycosides
|
|
US2008071364A1
|
|
Treating valve failure
|
|
AU2003264170A1
|
|
Cholesterol efflux and uses thereof
|
|
AU2003257262A8
|
|
Peptidomimetic drugs
|
|
AU2003903363A0
|
|
Methods and compositions for treating disorders of the extracellular matrix
|
|
AU2003229364A1
|
|
Therapeutic target and uses thereof
|
|
EP1501791A1
|
|
Amino acid analogues
|
|
AU2003212108A1
|
|
Method of analysis of circadian rhythms
|
|
AU2002953480A0
|
|
Methods of treating cardiovascular disease
|
